The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
The CGTP 2020 Symposium will explore how to continue to adapt concepts applied to other biologics and how to establish novel approaches where they are needed.
Innovative regulatory pathways for cell and gene products have accelerated product development and approval allowing patients in need to access transformative therapies. However, the shortened development timeline has exerted significant pressure to accelerated CMC development.
One of the biggest challenges is to develop, characterize, and validate the manufacturing process under these compressed clinical development timelines while ensuring comparability between process versions and maintaining the link to clinical data. In the past few years, several cell and gene therapy products have overcome this challenge and successfully launched new CGTPs. This session will provide the challenges industry is facing and approaches to speed up the CMC development. Perspectives from regulators will help set the expectations of CMC acceleration and pathways to facilitate innovation.
Specifically, the session will demonstrate how risk assessments are leveraged to guide process development activities for these products to ensure that the CGTP can be manufactured commercially and meet the CQAs established during registration trials.
Comparability is a significant challenge for advanced therapies due to issues such as complexity of the products, limited amounts of material available for testing, patient-specific variability, and short shelf life…
With the significant progression of late stage cell and gene therapy products, and the market approval of personal therapies, manufacturing of these complex products requires advanced technologies. With the reality of no inventory (e.g…